Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic
Grau, Santiago (Universitat Autònoma de Barcelona. Departament de Medicina)
Echeverría-Esnal, Daniel (Institut Hospital del Mar d'Investigacions Mèdiques)
Gómez-Zorrilla, Silvia (Institut Hospital del Mar d'Investigacions Mèdiques)
Navarrete-Rouco, Maria Eugenia (Institut Hospital del Mar d'Investigacions Mèdiques)
Masclans, Joan R (Universitat Autònoma de Barcelona. Departament de Medicina)
Espona, Merce (Institut Hospital del Mar d'Investigacions Mèdiques)
Gracia-Arnillas, Maria Pilar (Institut Hospital del Mar d'Investigacions Mèdiques)
Duran-Jordà, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques)
Comas Serrano, Mercè (Hospital del Mar (Barcelona, Catalunya))
Horcajada, Juan Pablo (Institut Hospital del Mar d'Investigacions Mèdiques)
Ferrández, Olivia (Institut Hospital del Mar d'Investigacions Mèdiques)

Fecha:	2021
Resumen:	Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of antimicrobial consumption during this period. Methods : A retrospective quasi-experimental before-after study was conducted in a Spanish tertiary care hospital. The study compared two periods: pre-pandemic, from January 2018 to February 2020, and during the COVID-19 pandemic from March to June 2020. Antimicrobial consumption was analyzed monthly as defined daily doses (DDD)/100 bed-days and overall hospital and ICU consumption were evaluated. Results: An increase in the hospital consumption was noticed. Although only ceftaroline achieved statistical significance (p = 0. 014), a rise was observed in most of the studied antimicrobials. A clear temporal pattern was detected. While an increase in ceftriaxone and azithromycin was observed during March, an increment in the consumption of daptomycin, carbapenems, linezolid, ceftaroline, novel cephalosporin/β-lactamase inhibitors or triazoles during April-May was noticed. In the ICU, these findings were more evident, namely ceftriaxone (p = 0. 029), carbapenems (p = 0. 002), daptomycin (p = 0. 002), azithromycin (p = 0. 030), and linezolid (p = 0. 011) but followed a similar temporal pattern. Conclusion : An increase in the antimicrobial consumption during the first wave of COVID-19 pandemic was noticed, especially in the ICU. Availability of updated protocols and antimicrobial stewardship programs are essential to optimize these outcomes.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Antimicrobial stewardship ; COVID-19 ; Defined daily doses (DDD) ; Antimicrobial resistance ; Antibiotic consumption
Publicado en:	Antibiotics, Vol. 10 (january 2021) , ISSN 2079-6382

DOI: 10.3390/antibiotics10020132
PMID: 33573070

11 p, 1.4 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados